{"url_path":"/sec/adxn/10-k/2026/item-9","section_key":"item-9","section_title":"Item 9 The Offer and Listing.","topic":"sec","document":{"doc_type":"20-F","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1574232/0001104659-26-062447-index.html","accession_number":"0001104659-26-062447","cik":"0001574232","ticker":"ADXN","issuer_name":"Addex Therapeutics Ltd.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1574232/0001104659-26-062447-index.html","primary_entity_key":"0001574232","primary_entity_name":"Addex Therapeutics Ltd."},"word_count":110,"has_tables":true,"body_markdown":"Item 9. The Offer and Listing.\n\nA.\n\nOffer and Listing Details.\n\nOur shares have been listed on Nasdaq Capital Market, or Nasdaq, under the symbol “ADXN” since January 29, 2020 and on the SIX Swiss Exchange, or SIX, under the symbol “ADXN” since May 22, 2007.\n\nB.\n\nPlan of Distribution.\n\nNot applicable.\n\nC.\n\nMarkets.\n\nOur shares have been listed on Nasdaq Capital Market, or Nasdaq, under the symbol “ADXN” since January 29, 2020 and on the SIX Swiss Exchange, or SIX, under the symbol “ADXN” since May 22, 2007.\n\nD.\n\nSelling Shareholders.\n\nNot applicable.\n\nE.\n\nDilution.\n\nNot applicable.\n\nF.\n\nExpenses of the Issue.\n\nNot applicable.\n\n​\n\n80\n\n[Table of Contents](#TOC)"}